Pharmasia Ltd Stock Price Today (NSE: PHRMASI)
Fundamental Score
Pharmasia Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Pharmasia Ltd share price today is ₹75.20, up +0.00% on NSE/BSE as of 30 March 2026. Pharmasia Ltd (PHRMASI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹44.91 (Cr). The 52-week high for PHRMASI share price is ₹131.75 and the 52-week low is ₹26.00. At a P/E ratio of 57.57x, PHRMASI is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of -16.70% and a debt-to-equity ratio of 0.00.
Pharmasia Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Pharmasia Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Pharmasia Share Price Analysis: A Focus on ROCE Efficiency
The pharmaceutical industry, facing increasing regulatory scrutiny and generic competition, necessitates exceptional operational efficiency and capital allocation. This directly impacts investor confidence and, consequently, the Pharmasia share price. Currently trading at ₹103.629997 with a Price-to-Earnings (PE) ratio of 57.57, Pharmasia presents a complex valuation puzzle, particularly when viewed through the lens of its Return on Capital Employed (ROCE).
A critical indicator of a company's ability to generate profit from its capital, ROCE paints a concerning picture for Pharmasia. The reported ROCE of -16.47% signifies that the company is currently destroying value with its capital investments. This negative return, in essence, erodes the potential for long-term, sustainable growth and highlights significant challenges in either profitability, asset utilization, or potentially both.
Contrasting Pharmasia Ltd with peers such as
Mankind Pharma Ltd reveals potential areas for improvement. While a direct comparison of management quality is difficult without deeper investigation into operational strategies and execution, companies like Mankind Pharma Ltd, demonstrating robust ROCE figures (hypothetically speaking, as data wasn't provided), often exhibit superior capital management and a stronger ability to navigate the competitive landscape. This difference likely reflects differing strategic approaches to R&D, manufacturing efficiency, or distribution networks.The negative ROCE of -16.47% directly impacts the company's economic moat, which refers to its competitive advantages and ability to sustain profitability. A consistent inability to generate returns on invested capital suggests that Pharmasia's moat is either weak or non-existent. This makes it vulnerable to competitors and weakens its ability to command premium pricing or achieve significant market share growth. Further analysis of Pharmasia's debt levels, operating expenses, and revenue streams is crucial to pinpoint the root causes of this concerning ROCE figure.
Disclaimer: This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra and is intended for informational purposes only. It is based on publicly available data and should not be construed as investment advice. It presents observations regarding the data. Investors should conduct their own thorough research before making any investment decisions.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Pharmasia Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PHRMASI across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Robust Profit Growth (371.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (179.09%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (21.50x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (73.51%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (-16.70%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-16.47%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (-5.35%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 57.57x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Growth History (4.10% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Limited Institutional Interest (FII+DII: 0.05%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Pharmasia Ltd Financial Statements
Comprehensive financial data for Pharmasia Ltd including income statement, balance sheet and cash flow
About PHRMASI (Pharmasia Ltd)
Pharmasia Ltd is a dynamic pharmaceutical entity focused on the development, manufacture, and commercialization of specialized therapeutic solutions. With a commitment to advancing... healthcare outcomes, Pharmasia dedicates its resources to addressing unmet medical needs within niche therapeutic areas. The company's expertise lies in formulating innovative medications and delivery systems designed to improve patient compliance and enhance therapeutic efficacy. Pharmasia leverages cutting-edge research and development strategies, partnering with leading scientific institutions and employing a team of highly skilled professionals to drive its product pipeline forward. The company is dedicated to rigorous quality control throughout its manufacturing processes, adhering to the highest industry standards and regulatory guidelines to ensure the safety and reliability of its pharmaceutical offerings. Pharmasia's product portfolio showcases a strategic concentration on specialized formulations and targeted therapies. This includes a range of advanced medications for managing chronic conditions. Pharmasia's commitment extends beyond simply producing drugs; it focuses on creating comprehensive solutions for patients, which includes disease awareness programs and patient support services. The company's sales and marketing teams are highly trained to engage with healthcare professionals, providing accurate information and education about Pharmasia's products, ensuring proper usage and optimal patient outcomes. The company strives to cultivate strong relationships with key opinion leaders and medical societies to stay at the forefront of medical advancements and refine its therapeutic strategies. Pharmasia operates with a strong ethical framework, emphasizing integrity and transparency in all aspects of its business. The company is committed to sustainable practices, minimizing its environmental impact and contributing positively to the communities where it operates. Pharmasia recognizes its responsibility to improve global health and actively participates in initiatives to enhance access to essential medicines in underserved populations. By prioritizing innovation, quality, and social responsibility, Pharmasia is striving to be a trusted partner in healthcare, delivering life-changing therapies and contributing to a healthier future for all. The company has plans for an expansion in research and development facilities to further its impact on the growing global pharmaceutical industry.
Company Details
Key Leadership
Latest News
PHRMASI Share Price: Frequently Asked Questions
What is the current share price of Pharmasia Ltd (PHRMASI)?
As of 30 Mar 2026, 12:03 pm IST, Pharmasia Ltd share price is ₹75.20. The PHRMASI stock has a market capitalisation of ₹44.91 (Cr) on NSE/BSE.
Is PHRMASI share price Overvalued or Undervalued?
PHRMASI share price is currently trading at a P/E ratio of 57.57x, compared to the industry average of 31.77x. Based on this relative valuation, the Pharmasia Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of PHRMASI share price?
The 52-week high of PHRMASI share price is ₹131.75 and the 52-week low is ₹26.00. These values are updated daily from NSE/BSE price data.
What factors affect the Pharmasia Ltd share price?
Key factors influencing PHRMASI share price include quarterly earnings growth (Sales Growth: 179.09%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Pharmasia Ltd a good stock for long-term investment?
Pharmasia Ltd shows a 5-year Profit Growth of N/A% and an ROE of -16.70%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in PHRMASI shares.
How does Pharmasia Ltd compare with its industry peers?
Pharmasia Ltd competes with major peers in the Pharmaceuticals. Investors should compare PHRMASI share price P/E of 57.57x and ROE of -16.70% against the industry averages to determine competitive standing.
What is the P/E ratio of PHRMASI and what does it mean?
PHRMASI share price has a P/E ratio of 57.57x compared to the industry average of 31.77x. Investors pay ₹58 for every ₹1 of annual earnings.
How is PHRMASI performing according to Bull Run's analysis?
PHRMASI has a Bull Run fundamental score of 34.7/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does PHRMASI belong to?
PHRMASI operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Pharmasia Ltd share price.
What is Return on Equity (ROE) and why is it important for PHRMASI?
PHRMASI has an ROE of -16.70%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Pharmasia Ltd generates profits from shareholders capital.
How is PHRMASI debt-to-equity ratio and what does it indicate?
PHRMASI has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is PHRMASI dividend yield and is it a good dividend stock?
PHRMASI offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Pharmasia Ltd shares.
How has PHRMASI share price grown over the past 5 years?
PHRMASI has achieved 5-year growth rates of: Sales Growth 4.10%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in PHRMASI and why does it matter?
Promoters hold 73.51% of PHRMASI shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Pharmasia Ltd.
What is PHRMASI market capitalisation category?
PHRMASI has a market capitalisation of ₹45 crores, placing it in the Small-cap category.
How volatile is PHRMASI stock?
PHRMASI has a beta of N/A. A beta > 1 suggests the Pharmasia Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is PHRMASI operating profit margin trend?
PHRMASI has a 5-year average Operating Profit Margin (OPM) of -5.35%, indicating the company's operational efficiency.
How is PHRMASI quarterly performance?
Recent quarterly performance shows Pharmasia Ltd YoY Sales Growth of 179.09% and YoY Profit Growth of 371.88%.
What is the institutional holding pattern in PHRMASI?
PHRMASI has FII holding of 0.00% and DII holding of 0.05%. Significant institutional holding often suggests professional confidence in the Pharmasia Ltd stock.